Advanced search
Publication Cover
Future Cardiology Volume 19, 2023 - Issue 4
Submit an article Journal homepage
472
Views
0
CrossRef citations to date
0
Altmetric
Letter in Reply

Letter in Reply: A Letter to the Editor Commenting on the Recent Publication By AY Avidan and CA Kushida

Alon Y Avidan1 David Geffen School of Medicine at UCLALos AngelesCA90095
&
Clete A Kushida2 Department of Psychiatry & Behavioral SciencesStanford University Medical CenterPalo AltoCA94305USAUSACorrespondence[email protected]
Pages 185-188 | Received 16 Jan 2023, Accepted 20 Apr 2023, Published online: 06 Jun 2023

References

  • Macfadden W , WilhelmA, CandlerS, MettamS. A letter to the editor commenting on the recent publication by AY Avidan and CA Kushida. Future Cardiol.18(12), 921–923 (2022).
  • Avidan AY , KushidaCA. Is the sodium in sodium oxybate a risk for heart health? A plain language summary of publication. Future Cardiol.18(5), 359–365 (2022).
  • O'Donnell M , MenteA, AldermanMHet al. Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. Eur. Heart J.41(35), 3363–3373 (2020).
  • Mancia G , OparilS, WheltonPKet al. The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. Eur. Heart J.38(10), 712–719 (2017).
  • Mente A , O'DonnellM, YusufS. Sodium intake and health: what should we recommend based on the current evidence?Nutrients13(9), 3232 (2021).
  • Hogas M , StatescuC, PadurariuMet al. Salt, not always a cardiovascular enemy? A mini-review and modern perspective. Medicina (Kaunas)58(9), 1175 (2022).
  • Patel Y , JosephJ. Sodium intake and heart failure. Int. J. Mol. Sci.21(24), 9474 (2020).
  • Ezekowitz JA , Colin-RamirezE, RossHet al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet399(10333), 1391–1400 (2022).
  • Zhou TL , SchuttenMTJ, KroonAAet al. Urinary sodium excretion and salt intake are not associated with blood pressure variability in a white general population. J. Am. Heart Assoc.12(1), e026578 (2023).
  • XYREM (sodium oxybate oral solution, CIII). Full prescribing information. Jazz Pharmaceuticals, Inc., CA, USA (2022).
  • Wang YG , SwickTJ, CarterLP, ThorpyMJ, BenowitzNL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J. Clin. Sleep Med.5(4), 365–371 (2009).
  • Wang YG , SwickTJ, CarterLP, ThorpyMJ, BenowitzNL. Sodium oxybate: updates and correction to previously published safety data. J. Clin. Sleep Med.7(4), 415–416 (2011).
  • Avidan AY , KushidaCA. The sodium in sodium oxybate: is there cause for concern?Sleep Med.75, 497–501 (2020).
  • XYWAV (calcium, magnesium, potassium, and sodium oxybates oral solution, CIII). Full prescribing information. Jazz Pharmaceuticals, Inc., CA, USA (2022).
  • Ben-Joseph RH , SomersVK, BlackJet al. Hypertension onset among narcolepsy patients newly treated with sodium oxybate. Presented at: Psych Congress.CA, USA (September 17–20, 2022).
  • Leggio M , LombardiM, CaldaroneEet al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertens. Res.40(12), 947–963 (2017).
  • Ha SK . Dietary salt intake and hypertension. Electrolyte Blood Press12(1), 7–18 (2014).
  • Stamler J , ChanQ, DaviglusMLet al. Relation of dietary sodium (Salt) to blood pressure and its possible modulation by other dietary factors: the INTERMAP Study. Hypertension71(4), 631–637 (2018).
  • Bogan RK , ThorpyMJ, DauvilliersYet al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep44(3), zsaa206 (2021).
  • Aburto NJ , ZiolkovskaA, HooperL, ElliottP, CappuccioFP, MeerpohlJJ. Effect of lower sodium intake on health: systematic review and meta-analyses. Brit. Med. J.346, f1326 (2013).
  • Jazz Pharmaceuticals . Jazz Pharmaceuticals announces third quarter 2022 financial results and raises total revenue guidance mid-point (2022). https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-third-quarter-2022-financial
  • LUMRYZ (sodium oxybate for extended-release oral suspension CIII) . Avadel Pharmaceuticals, MO, USA (2023).
  • US Food and Drug Administration . Clinical superiority findings. MD, USA (2023). www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.